(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are IMAC Holdings, Akerna Corp., and Lion Group Holding Ltd..

The three biggest losers today are Malacca Straits Acquisition Company Limited, Ideanomics, and Groupon.

Winners today

1. IMAC Holdings (IMACW) – 354.55%

NASDAQ ended the session with IMAC Holdings jumping 354.55% to $0.02 on Tuesday, after five sequential sessions in a row of losses. NASDAQ dropped 0.16% to $13,667.29, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Yearly Top and Bottom Value

IMAC Holdings’s stock is valued at $0.02 at 17:32 EST, way under its 52-week low of $0.00.

More news about IMAC Holdings.

2. Akerna Corp. (KERNW) – 49.25%

NASDAQ ended the session with Akerna Corp. jumping 49.25% to $0.01 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ fell 0.16% to $13,667.29, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Yearly Top and Bottom Value

Akerna Corp.’s stock is valued at $0.01 at 17:32 EST, under its 52-week high of $0.01 and way above its 52-week low of $0.01.

More news about Akerna Corp..

3. Lion Group Holding Ltd. (LGHLW) – 33.93%

NASDAQ ended the session with Lion Group Holding Ltd. jumping 33.93% to $0.02 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ fell 0.16% to $13,667.29, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Yearly Top and Bottom Value

Lion Group Holding Ltd.’s stock is valued at $0.02 at 17:32 EST, way higher than its 52-week high of $0.02.

More news about Lion Group Holding Ltd..

4. Virgin Galactic (SPCE) – 24.74%

Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico.

NYSE ended the session with Virgin Galactic rising 24.74% to $5.90 on Tuesday, after two successive sessions in a row of gains. NYSE dropped 0.93% to $15,648.92, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Virgin Galactic (spce) to launch first commercial space flightThe share price for Virgin Galactic Holdings, Inc. (SPCE Quick QuoteSPCE – Free Report) has been skyrocketing since the beginning of June, increasing 36.7% as of last week. , Founded in 2004 by billionaire and commercial astronaut Richard Branson, Virgin Galactic is part of the Zacks Aerospace - Defense industry.

Earnings Per Share

As for profitability, Virgin Galactic has a trailing twelve months EPS of $-2.26.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Virgin Galactic’s stock is considered to be oversold (<=20).

Sales Growth

Virgin Galactic’s sales growth is 605.9% for the current quarter and 366.8% for the next.

More news about Virgin Galactic.

5. Medigus Ltd. (MDGSW) – 22.5%

NASDAQ ended the session with Medigus Ltd. rising 22.5% to $0.05 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ slid 0.16% to $13,667.29, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Yearly Top and Bottom Value

Medigus Ltd.’s stock is valued at $0.05 at 17:32 EST, way under its 52-week high of $0.09 and higher than its 52-week low of $0.05.

More news about Medigus Ltd..

6. Gyrodyne (GYRO) – 20%

Gyrodyne, LLC owns and manages a diversified portfolio of real estate properties comprising office, industrial and service-oriented properties in the New York metropolitan area. Gyrodyne owns a 63 acre site approximately 50 miles east of New York City on the north shore of Long Island, which includes industrial and office buildings and undeveloped property which is the subject of plans to seek value-enhancing entitlements. Gyrodyne also owns a medical office park in Cortlandt Manor, New York which is also the subject of a subdivision application. Gyrodyne's common shares are traded on the NASDAQ Stock Market under the symbol GYRO.

NASDAQ ended the session with Gyrodyne jumping 20% to $11.70 on Tuesday while NASDAQ dropped 0.16% to $13,667.29.

Earnings Per Share

As for profitability, Gyrodyne has a trailing twelve months EPS of $0.18.

PE Ratio

Gyrodyne has a trailing twelve months price to earnings ratio of 65. Meaning, the purchaser of the share is investing $65 for every dollar of annual earnings.

More news about Gyrodyne.

7. Marathon (MARA) – 17.03%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon rising 17.03% to $11.68 on Tuesday while NASDAQ dropped 0.16% to $13,667.29.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-6.16.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -103.2%.

More news about Marathon.

8. Lyra Therapeutics (LYRA) – 16.5%

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

NASDAQ ended the session with Lyra Therapeutics jumping 16.5% to $3.53 on Tuesday while NASDAQ fell 0.16% to $13,667.29.

Earnings Per Share

As for profitability, Lyra Therapeutics has a trailing twelve months EPS of $-1.41.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -133.46%.

Moving Average

Lyra Therapeutics’s value is way higher than its 50-day moving average of $2.59 and higher than its 200-day moving average of $3.33.

More news about Lyra Therapeutics.

9. aTyr Pharma (LIFE) – 10.86%

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product ATYR1923 is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

NASDAQ ended the session with aTyr Pharma rising 10.86% to $2.45 on Tuesday, following the last session’s upward trend. NASDAQ dropped 0.16% to $13,667.29, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, aTyr Pharma has a trailing twelve months EPS of $-1.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.39%.

Moving Average

aTyr Pharma’s value is way higher than its 50-day moving average of $2.19 and higher than its 200-day moving average of $2.35.

Volume

Today’s last reported volume for aTyr Pharma is 2376930 which is 245.34% above its average volume of 688287.

Yearly Top and Bottom Value

aTyr Pharma’s stock is valued at $2.45 at 17:32 EST, way under its 52-week high of $4.28 and way above its 52-week low of $1.56.

More news about aTyr Pharma.

10. Immatics N.V. (IMTXW) – 10.5%

NASDAQ ended the session with Immatics N.V. rising 10.5% to $3.79 on Tuesday, after five sequential sessions in a row of losses. NASDAQ slid 0.16% to $13,667.29, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Yearly Top and Bottom Value

Immatics N.V.’s stock is valued at $3.79 at 17:32 EST, under its 52-week low of $3.67.

More news about Immatics N.V..

Losers Today

1. Malacca Straits Acquisition Company Limited (MLACW) – -41.67%

NASDAQ ended the session with Malacca Straits Acquisition Company Limited sliding 41.67% to $0.00 on Tuesday, after five successive sessions in a row of losses. NASDAQ dropped 0.16% to $13,667.29, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

More news about Malacca Straits Acquisition Company Limited.

2. Ideanomics (IDEX) – -18.68%

Ideanomics, Inc. focuses on driving the adoption of commercial electric vehicles, associated energy consumption, and developing financial services and fintech products. Its Ideanomics Mobility division facilitates the adoption of electric vehicles by commercial fleet operators. This division also offers solutions for the procurement, financing, charging, and energy management needs for fleet operators of commercial electric vehicles. The company's Ideanomics Capital division provides fintech services, which focuses on the enhancement of efficiency, transparency, and profitability for the financial services industry. Ideanomics, Inc. was incorporated in 2004 and is headquartered in New York, New York.

NASDAQ ended the session with Ideanomics falling 18.68% to $0.08 on Tuesday while NASDAQ dropped 0.16% to $13,667.29.

Earnings Per Share

As for profitability, Ideanomics has a trailing twelve months EPS of $-0.41.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -109.94%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Ideanomics’s EBITDA is -0.63.

Volatility

Ideanomics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 6.95%, a positive 1.22%, and a positive 20.84%.

Ideanomics’s highest amplitude of average volatility was 18.06% (last week), 21.22% (last month), and 20.84% (last quarter).

Volume

Today’s last reported volume for Ideanomics is 137403000 which is 43.66% above its average volume of 95644400.

Revenue Growth

Year-on-year quarterly revenue growth declined by 37.8%, now sitting on 100.94M for the twelve trailing months.

More news about Ideanomics.

3. Groupon (GRPN) – -12.17%

Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with Groupon falling 12.17% to $4.33 on Tuesday, after two sequential sessions in a row of gains. NASDAQ dropped 0.16% to $13,667.29, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Groupon has a trailing twelve months EPS of $-7.98.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -285.15%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Groupon’s EBITDA is 0.51.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 47.1% and 108.8%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Groupon’s stock is considered to be oversold (<=20).

Volume

Today’s last reported volume for Groupon is 1119550 which is 12.2% below its average volume of 1275180.

More news about Groupon.

4. Integrated Media Technology Limited (IMTE) – -11.57%

Integrated Media Technology Limited develops, sells, and distributes 3D autostereoscopic display (ASD) technology products and services in Hong Kong, China, Korea, Singapore, and Australia. The company focuses on the marketing and sale of autostereoscopic display (ASD) products; ASD technology displays and marvel3DPro super-workstations; lenticular hardware and switchable lenticular hardware products; ASD digital signage displays; switchable glass products; Internet of Things products; and nano-coating plated air filters. It also engages in the business of risk analytics; healthcare technologies to assisted healthcare, age homes, and self-care homes; and sale of software and provision of consultancy services. In addition, the company offers management; administrative; and digital picture frame services. It serves the construction and real estate industry, including train stations, airports, convention centers, commercial offices, hospitals, and residential homes and apartments. The company was formerly known as China Integrated Media Corporation Limited and changed its name to Integrated Media Technology Limited in October 2016. Integrated Media Technology Limited was incorporated in 2008 and is headquartered in Wan Chai, Hong Kong.

NASDAQ ended the session with Integrated Media Technology Limited sliding 11.57% to $0.45 on Tuesday, following the last session’s downward trend. NASDAQ dropped 0.16% to $13,667.29, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Integrated Media Technology Limited has a trailing twelve months EPS of $-0.46.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.75%.

More news about Integrated Media Technology Limited.

5. Leap Therapeutics (LPTX) – -10.29%

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

NASDAQ ended the session with Leap Therapeutics falling 10.29% to $0.61 on Tuesday while NASDAQ slid 0.16% to $13,667.29.

Earnings Per Share

As for profitability, Leap Therapeutics has a trailing twelve months EPS of $-0.77.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -88.47%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 40% and 46.2%, respectively.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Leap Therapeutics’s EBITDA is -66.81.

Volume

Today’s last reported volume for Leap Therapeutics is 324837 which is 66.81% below its average volume of 978759.

Yearly Top and Bottom Value

Leap Therapeutics’s stock is valued at $0.61 at 17:32 EST, way under its 52-week high of $1.86 and way above its 52-week low of $0.27.

More news about Leap Therapeutics.

6. Mustang Bio (MBIO) – -10.25%

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

NASDAQ ended the session with Mustang Bio falling 10.25% to $7.18 on Tuesday while NASDAQ slid 0.16% to $13,667.29.

Earnings Per Share

As for profitability, Mustang Bio has a trailing twelve months EPS of $-11.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -117.07%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 36.5% and 41.5%, respectively.

Moving Average

Mustang Bio’s worth is way above its 50-day moving average of $4.77 and above its 200-day moving average of $6.85.

More news about Mustang Bio.

7. Luokung Technology Corp (LKCO) – -10.14%

Luokung Technology Corp., together with its subsidiaries, provides location-based services and mobile application products for long distance travelers in the People's Republic of China. It offers Luokuang mobile application, a content and service distribution platform that provides content and services, such as information, entertainment, travel, e-commerce, online to offline, advertisement, and other marketing features. The company also offers software development kits and application-programming interfaces, which provide spatial-temporal big data analysis and customized map to software and mobile application developers; and spatial temporal indexing cloud service, a data-level virtualization technology. In addition, it offers information SuperEngine that includes the server engine, which enables to store, manage, and index the spatial temporal big data on the server side; and Web graphics image engine that supports transmission of graphics images, as well as display and edge computing for multi-terminal and cross-platform. Further, the company provides spatial temporal cloud platform that offers cloud services, including data storage, data resource, and platform support services, as well as supports users to aggregate multi-source spatial data, map services, and Internet of Things streaming data. Luokung Technology Corp. has a strategic partnership with Jiangsu Dianyu Information Technology Co., Ltd. to expand mobile commercial big data services in the 5G era. The company is headquartered in Beijing, China.

NASDAQ ended the session with Luokung Technology Corp falling 10.14% to $1.24 on Tuesday, following the last session’s downward trend. NASDAQ fell 0.16% to $13,667.29, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Luokung Technology Corp has a trailing twelve months EPS of $-3.37.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.85%.

More news about Luokung Technology Corp.

8. Bilibili (BILI) – -8.84%

Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. Its platform offers a range of content, including video services, mobile games, and value-added service, as well as ACG-related comic and audio content. The company's video services include professional user generated videos, occupationally generated videos, live broadcasting, and story mode. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.

NASDAQ ended the session with Bilibili falling 8.84% to $15.93 on Tuesday, following the last session’s downward trend. NASDAQ fell 0.16% to $13,667.29, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Bilibili has a trailing twelve months EPS of $-2.04.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.59%.

Sales Growth

Bilibili’s sales growth is 7.4% for the current quarter and 9.1% for the next.

More news about Bilibili.

9. Zai Lab (ZLAB) – -8.59%

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

NASDAQ ended the session with Zai Lab falling 8.59% to $26.58 on Tuesday while NASDAQ dropped 0.16% to $13,667.29.

Earnings Per Share

As for profitability, Zai Lab has a trailing twelve months EPS of $-4.41.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.51%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Zai Lab’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth grew by 34.4%, now sitting on 231.11M for the twelve trailing months.

Moving Average

Zai Lab’s worth is way below its 50-day moving average of $33.80 and way under its 200-day moving average of $35.63.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 47.2% and 54.2%, respectively.

More news about Zai Lab.

10. DAQO New Energy (DQ) – -8.39%

Daqo New Energy Corp., together with its subsidiaries, manufactures and sells polysilicon to photovoltaic product manufacturers in the People's Republic of China. Its products are used in ingots, wafers, cells, and modules for solar power solutions. The company was formerly known as Mega Stand International Limited and changed its name to Daqo New Energy Corp. in August 2009. Daqo New Energy Corp. was founded in 2006 and is based in Shanghai, the People's Republic of China.

NYSE ended the session with DAQO New Energy sliding 8.39% to $39.07 on Tuesday while NYSE fell 0.93% to $15,648.92.

Earnings Per Share

As for profitability, DAQO New Energy has a trailing twelve months EPS of $20.31.

PE Ratio

DAQO New Energy has a trailing twelve months price to earnings ratio of 1.92. Meaning, the purchaser of the share is investing $1.92 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 42.76%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 44.6%, now sitting on 4.04B for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

DAQO New Energy’s EBITDA is -0.19.

Volume

Today’s last reported volume for DAQO New Energy is 521842 which is 50% below its average volume of 1043750.

More news about DAQO New Energy.

Stay up to date with our winners and losers daily report